IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, and NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercialization of radiopharmaceuticals used for medical imaging and therapeutic applications, today announced a collaboration to increase global availability of technetium-99m, the most widely used medical radioisotope. The collaboration enables companies outside of the United States to access the Tc-99m Generation Systems that utilize NorthStar’s proprietary non-uranium based Mo-99 produced using IBA’s accelerators and beamlines.
To read more please visit:
Source: IBA